CERo Therapeutics Holdings, Inc. receives critical patents for cancer treatment

From GlobeNewswire: 2025-04-10 08:15:00

CERo Therapeutics Holdings, Inc. has received allowance for two patent applications from the USPTO, expanding their intellectual property portfolio. The patents cover composition of matter and methods for their lead compound CER-1236, showing potential for cancer treatment. With these approvals, CERo now has 17 issued and allowed patents internationally across nine patent families, ensuring protection until 2039. CEO Chris Ehrlich emphasizes the significance of these patents in validating CERo’s innovative approach to cancer therapy. The company’s unique cellular immunotherapy platform aims to develop T cell therapeutics for both hematological malignancies and solid tumors, with clinical trials for lead candidate CER-1236 set to begin in 2025.



Read more at GlobeNewswire: CERo Therapeutics Holdings, Inc. Announces Critical Patent